๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

30 recruiting trials

for Breast Cancer (Triple Negative Breast Cancer (TNBC))

A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) NCT07743190Phase 22 sites๐Ÿ“ Syracuse๐Ÿ“ Charleston Medical University of South Carolina ยท Tests: Carboplatin, Paclitaxcel, Pembrolizumab PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC NCT06245889Phase 22 sites๐Ÿ“ Baltimore๐Ÿ“ Baltimore Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins ยท Tests: Paclitaxel, Carboplatin, Pembrolizumab, Doxorubicin, Cyclophosphamide Viscum Album for TNBC on Adjuvant Pembrolizumab NCT06920810Phase 41 site๐Ÿ“ Goyang-si Ilsan Cha hospital ยท Tests: viscum album I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer NCT01042379Phase 242 sites๐Ÿ“ Birmingham๐Ÿ“ Scottsdale๐Ÿ“ Tucson QuantumLeap Healthcare Collaborative ยท Tests: Standard Therapy, AMG 386 with or without Trastuzumab, AMG 479 (Ganitumab) plus Metformin, MK-2206 with or without Trasโ€ฆ Personalizing the Use of Pembrolizumab for Patients Who Have a Strong Response in Early Triple Negative Breast Cancer NCT06606730Phase 32 sites๐Ÿ“ Brussels๐Ÿ“ Villejuif UNICANCER ยท Tests: Pembrolizumab, Deescalation AK112 or Placebo Plus Nab-Paclitaxel as First-line Treatment in Inoperable Locally Advanced/ Metastatic Triple-negative Breast Cancer NCT06767527Phase 31 site๐Ÿ“ Beijing Akeso ยท Tests: AK112, Nab-paclitaxel, Placebo A Phase 0 Multicenter Study of the Pharmacodynamic Effects of Intratumoral Microdose Administration of PBA-0111 in Patients With Solid Tumors NCT06700070EARLY Phase 11 site๐Ÿ“ Shreveport Pure Biologics S.A. ยท Tests: PBA-0111 Preoperative Chemotherapy, Pembrolizumab and Low or High Dose RADiation in an Expansion Cohort of Node(+), Triple Negative Breast Cancer NCT07276880Phase 21 site๐Ÿ“ Chapel Hill UNC Lineberger Comprehensive Cancer Center ยท Tests: Neoadjuvant Pembrolizumab, low dose neoadjuvant boost, High dose neoadjuvant boost PHOENIX DDR/Anti-PD-L1 Trial: A Pre-surgical Window of Opportunity and Post-surgical Adjuvant Biomarker Study of DNA Damage Response Inhibition With or Without Anti-PD-L1 Immunotherapy in Patients With Neoadjuvant Treatment Resistant Residual Triple Negative Breast Cancer NCT03740893Phase 26 sites๐Ÿ“ Bournemouth๐Ÿ“ London๐Ÿ“ Manchester Institute of Cancer Research, United Kingdom ยท Tests: AZD6738, Olaparib, Durvalumab Use of Imatinib to Convert Triple Negative Breast Cancer Into ER-positive Breast Cancer (I-CONIC) NCT05722795NA1 site๐Ÿ“ Gothenburg Vastra Gotaland Region ยท Tests: Imatinib 400 MG Oral Tablet Evaluating Minimal Residual Disease (MRD) Through Longitudinal Circulating Tumor DNA (ctDNA) Profiling in Breast Malignancies NCT07211178n/a16 sites๐Ÿ“ Birmingham๐Ÿ“ Whittier๐Ÿ“ Weston Tempus AI ยท Tests: There are no interventions in this observational study. Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer NCT07652242Phase 12 sites๐Ÿ“ Grand Rapids๐Ÿ“ Nashville Immunomic Therapeutics, Inc. ยท Tests: ITI-5000 mRNA Vaccine, Pembrolizumab, ITI-5000 mRNA Vaccine, Olaparib, Capecitabine PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer NCT07190469Phase 14 sites๐Ÿ“ Houston๐Ÿ“ San Antonio๐Ÿ“ West Valley City ProteinQure Inc. ยท Tests: PQ203 ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer NCT07173751Phase 3224 sites๐Ÿ“ Springdale๐Ÿ“ La Jolla๐Ÿ“ Los Alamitos BioNTech SE ยท Tests: Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin Neoadjuvant Chemotherapy Combined With Sintilimab and Bevacizumab for TNBC (NEOTORCH-BREAST07) NCT07351487Phase 22 sites๐Ÿ“ Hefei๐Ÿ“ Shanghai First Affiliated Hospital of Zhejiang University ยท Tests: Neoadjuvant chemotherapy combined with Sintilimab and Bevacizumab QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC NCT06786026Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: bevacizumab, QL1706, Nab paclitaxel NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) NCT06081244Phase 343 sites๐Ÿ“ Baden-Baden๐Ÿ“ Bรถblingen๐Ÿ“ Freiburg im Breisgau Women's Cancer Study Group GmbH ยท Tests: Sacituzumab govitecan, Pembrolizumab A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC) NCT07208149Phase 1, Phase 21 site๐Ÿ“ Beijing Shenzhen Majory Biotechnology Co., Ltd. ยท Tests: MR001 Bispecific Antibody for Injection Efficacy and Safety of Tenalisib in Patients With Metastatic Triple Negative Breast Cancer (TNBC) NCT06189209Phase 29 sites๐Ÿ“ Vijayawada๐Ÿ“ Bangalore๐Ÿ“ Mumbai Rhizen Pharmaceuticals SA ยท Tests: Tenalisib Study Of Capecitabine Combined With Camrelizumab For Non-pCR TNBC With TLS After Neoadjuvant Chemoterapy NCT06313463Phase 31 site๐Ÿ“ Guangzhou Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University ยท Tests: Carrellizumab + Capecitabine, Placebo + Capecitabine A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674Phase 117 sites๐Ÿ“ Duarte๐Ÿ“ Los Angeles๐Ÿ“ San Francisco Nurix Therapeutics, Inc. ยท Tests: NX-1607, Paclitaxel The Efficacy and Safety of Utidelone Plus Tirelizumab and Bevacizumab for Advanced or Metastatic Triple-negative Breast Cancer (UTILIZABLE) ๏ผšSingle-arm, Prospective, Open Clinical Study NCT06125080Phase 21 site๐Ÿ“ Wuhan Huihua Xiong ยท Tests: Utidelone, Tirelizumab, Bevacizumab Circadian Rhythm Impact on TNBC Response to Neoadjuvant Immunotherapy NCT06880029Phase 1, Phase 21 site๐Ÿ“ Vila Nova de Gaia Centro Hospitalar de Vila Nova de Gaia/Espinho, E.P.E. ยท Tests: Morning pembrolizumab infusions The Optimal Radioimmunotherapy Combinations for Advanced TNBC NCT06735131Phase 21 site๐Ÿ“ Guangzhou Sun Yat-sen University ยท Tests: radiotherapy 5 Gy ร— 5 fractions, once a day, radiotherapy 8 Gy ร— 5 fractions, once a day, radiotherapy 8 Gy ร— 3 fractioโ€ฆ Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC NCT05192798Phase 21 site๐Ÿ“ Bengbu The First Affiliated Hospital of Bengbu Medical University ยท Tests: Albumin-Bound Paclitaxel, Apatinib Mesylate, Bevacizumab A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) NCT05999149Phase 32 sites๐Ÿ“ Shanghai๐Ÿ“ Shanghai Fudan University ยท Tests: Camrelizumab Plus Chemotherapy and Famitinib, Camrelizumab Plus Chemotherapy Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC NCT05464082Phase 21 site๐Ÿ“ Salt Lake City University of Utah ยท Tests: Functional Precision Oncology A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. NCT06371274NA1 site๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: ATRA, Toripalimab Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) NCT06682195Phase 213 sites๐Ÿ“ Nanchang๐Ÿ“ Hangzhou๐Ÿ“ Hangzhou First Affiliated Hospital of Zhejiang University ยท Tests: Neoadjuvant chemotherapy combined with Toripalimab Immunotherapy-related CRP Kinetics in Early and Metastatic Triple-negative Breast Cancer NCT05914961n/a1 site๐Ÿ“ Tรผbingen University Hospital Tuebingen
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy